


## WHAT IS CLAIMED IS:


1. A compound of Formula I:



5

wherein:

Y is selected from:



10 ----- represents an optional double bond;

X is C, N, S(O)<sub>m</sub> or O;

G is H<sub>2</sub> or O;

R<sup>a</sup> is independently selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) Halogen,
- 4) Aryl,
- 5) Heterocycle,
- 6) C<sub>3</sub>-C<sub>10</sub> cycloalkyl, or
- 7) OR<sup>4</sup>;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>1</sup> is independently selected from:

- 1) H,
- 2) (CR<sup>a</sup><sub>2</sub>)<sub>n</sub>R<sup>6</sup>,
- 3) (CR<sup>a</sup><sub>2</sub>)<sub>n</sub>C(O)R<sup>4</sup>,
- 4) C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 5) (CR<sup>a</sup><sub>2</sub>)<sub>n</sub>OR<sup>4</sup>,
- 6) (CR<sup>a</sup><sub>2</sub>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 7) S(O)<sub>m</sub>R<sup>6</sup>,
- 8) S(O)<sub>m</sub>R<sup>6</sup>OR<sup>4</sup>,
- 9) C(O)N(R<sup>4</sup>)(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>R<sup>6</sup>,
- 10) C(O)N(R<sup>4</sup>)(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>OR<sup>4</sup>,
- 11) C(O)R<sup>6</sup>(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>R<sup>6</sup>,
- 12) C(O)N(R<sup>4</sup>)(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>S(O)<sub>m</sub>(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>R<sup>6</sup>,
- 13) C(O)N(R<sup>4</sup>)(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>C(O)R<sup>6</sup>,
- 14) C(O)N(R<sup>4</sup>)(CR<sup>a</sup><sub>2</sub>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 15) Halogen,
- 16) N(R<sup>4</sup>)S(O)<sub>m</sub>R<sup>6</sup>,
- 17) (CR<sup>a</sup><sub>2</sub>)<sub>n</sub>C(O)OR<sup>4</sup>, and
- 18) R<sup>6</sup>C(O)OR;

R<sup>2</sup> is:

- 1) H,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,

- 3)  $N(R^4)_2$ ,
- 4)  $OR^4$ ,
- 5) unsubstituted or substituted aryl, and
- 6) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

5

$R^4$  is independently selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 10 4) Aryl,
- 5) Heterocycle,
- 6)  $CF_3$ ,
- 7) C<sub>2</sub>-C<sub>6</sub> alkenyl, and
- 8) C<sub>2</sub>-C<sub>6</sub> alkynyl;

15

said alkyl, cycloalkyl, aryl, heterocycle, alkenyl and alkynyl is optionally substituted with at least one substituent selected from  $R^7$ ;

$R^5$  is independently selected from:

- 20 1) H,
- 2) Halogen,
- 3)  $NO_2$ ,
- 4) CN,
- 5)  $CR^4=C(R^4)_2$ ,
- 25 6)  $C\equiv CR^4$ ,
- 7)  $(CR^{a2})_nOR^4$ ,
- 8)  $(CR^{a2})_nN(R^4)_2$ ,
- 9)  $C(O)R^4$ ,
- 10)  $C(O)OR^4$ ,
- 30 11)  $(CR^{a2})_nR^4$ ,
- 12)  $S(O)_mR^6$ ,
- 13)  $S(O)_mN(R^4)_2$ ,
- 14)  $OS(O)_mR^6$ ,
- 15)  $N(R^4)C(O)R^4$ ,

- 16)  $N(R^4)S(O)_mR^6$ ,
- 17)  $(CR^{a2})_nN(R^4)R^6$ ,
- 18)  $(CR^{a2})_nN(R^4)R^6OR^4$ ,
- 19)  $(CR^{a2})_nN(R^4)(CR^{a2})_nC(O)N(R^4)_2$ ,
- 20)  $N(R^4)(CR^{a2})_nR^6$ ,
- 21)  $N(R^4)(CR^{a2})_nN(R^4)_2$ ,
- 22)  $(CR^{a2})_nC(O)N(R^4)_2$ ,
- 23)  $O(CR^{a2})_nC(O)OR^4$ , and
- 24)  $O(CR^{a2})_nC(O)N(R^4)_2$ ;

$R^6$  is independently selected from:

- 1)  $C_1$ - $C_6$  alkyl,
- 2) Aryl,
- 3) Heterocycle, and
- 4)  $C_3$ - $C_{10}$  cycloalkyl;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent of  $R^7$ ;

$R^7$  is independently selected from:

- 1) Unsubstituted or substituted  $C_1$ - $C_6$  alkyl,
- 2) Halogen,
- 3)  $OR^4$ ,
- 4)  $CF_3$ ,
- 5) Unsubstituted or substituted aryl,
- 6) Unsubstituted or substituted  $C_3$ - $C_{10}$  cycloalkyl,
- 7) Unsubstituted or substituted heterocycle,
- 8)  $S(O)_mN(R^4)_2$ ,
- 9)  $C(O)OR^4$ ,
- 10)  $C(O)R^4$ ,
- 11)  $CN$ ,
- 12)  $C(O)N(R^4)_2$ ,
- 13)  $N(R^4)C(O)R^4$ ,
- 14)  $NO_2$ ; and
- 15)  $S(O)_mR^6$ ;

m is independently 0, 1 or 2;

n is independently 0, 1, 2, 3, 4, 5 or 6;

s is 0 to 6;

t is 0, 1, or 2;

5 v is 0, 1 or 2;

w is 0, 1, 2, 3, or 4;


z is 1 or 2;

or a pharmaceutically acceptable salt or stereoisomer thereof.

10

2. The compound according to Claim 1, as illustrated by Formula

II:



wherein:

15

----- represents an optional double bond;

X is C, N, S(O)<sub>m</sub> or O;

20 G is H<sub>2</sub> or O;

R<sup>a</sup> is independently selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) Halogen,
- 4) Aryl,
- 5) Heterocycle,

25

6) C<sub>3</sub>-C<sub>10</sub> cycloalkyl, and

7) OR<sup>4</sup>;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent selected from R<sup>7</sup>;

5

R<sup>1</sup> is independently selected from:

- 1) H,
- 2) (CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 3) (CR<sup>a2</sup>)<sub>n</sub>C(O)R<sup>4</sup>,
- 10 4) C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 5) (CR<sup>a2</sup>)<sub>n</sub>OR<sup>4</sup>,
- 6) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 7) S(O)<sub>m</sub>R<sup>6</sup>,
- 8) S(O)<sub>m</sub>R<sup>6</sup>OR<sup>4</sup>,
- 15 9) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 10) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>OR<sup>4</sup>,
- 11) C(O)R<sup>6</sup>(CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 12) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>S(O)<sub>m</sub>(CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 13) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>C(O)R<sup>6</sup>,
- 20 14) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 15) Halogen,
- 16) N(R<sup>4</sup>)S(O)<sub>m</sub>R<sup>6</sup>,
- 17) (CR<sup>a2</sup>)<sub>n</sub>C(O)OR<sup>4</sup>, and
- 18) R<sup>6</sup>C(O)OR;

25

R<sup>2</sup> is:

- 1) H,
- 2) Unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) N(R<sup>4</sup>)<sub>2</sub>, or
- 30 4) OR<sup>4</sup>;

R<sup>4</sup> is independently selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,

- 5
- 3) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
  - 4) Aryl,
  - 5) Heterocycle,
  - 6) CF<sub>3</sub>,
  - 7) C<sub>2</sub>-C<sub>6</sub> alkenyl, and
  - 8) C<sub>2</sub>-C<sub>6</sub> alkynyl;

said alkyl, cycloalkyl, aryl, heterocycle, alkenyl and alkynyl is optionally substituted with at least one substituent selected from R<sup>7</sup>;

10

R<sup>5</sup> is independently selected from:

- 1) H,
- 2) Halogen,
- 3) NO<sub>2</sub>,
- 15 4) CN,
- 5) CR<sup>4</sup>=C(R<sup>4</sup>)<sub>2</sub>,
- 6) C≡CR<sup>4</sup>,
- 7) (CR<sup>a2</sup>)<sub>n</sub>OR<sup>4</sup>,
- 8) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 20 9) C(O)R<sup>4</sup>,
- 10) C(O)OR<sup>4</sup>,
- 11) (CR<sup>a2</sup>)<sub>n</sub>R<sup>4</sup>,
- 12) S(O)<sub>m</sub>R<sup>6</sup>,
- 13) S(O)<sub>m</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 25 14) OS(O)<sub>m</sub>R<sup>6</sup>,
- 15) N(R<sup>4</sup>)C(O)R<sup>4</sup>,
- 16) N(R<sup>4</sup>)S(O)<sub>m</sub>R<sup>6</sup>,
- 17) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)R<sup>6</sup>,
- 18) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)R<sup>6</sup>OR<sup>4</sup>,
- 30 19) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 20) N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 21) N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>, and
- 22) (CR<sup>a2</sup>)<sub>n</sub>C(O)N(R<sup>4</sup>)<sub>2</sub>;

R<sup>6</sup> is independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) Aryl,
- 3) Heterocycle, and
- 5 4) C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

said alkyl, aryl, heterocycle and cycloalkyl is optionally substituted with at least one substituent of R<sup>7</sup>;

R<sup>7</sup> is independently selected from:

- 10 1) Unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) Halogen,
- 3) OR<sup>4</sup>,
- 4) CF<sub>3</sub>,
- 5) Unsubstituted or substituted aryl,
- 15 6) Unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 7) Unsubstituted or substituted heterocycle,
- 8) S(O)<sub>m</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 9) C(O)OR<sup>4</sup>,
- 10) C(O)R<sup>4</sup>,
- 20 11) CN,
- 12) C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 13) N(R<sup>4</sup>)C(O)R<sup>4</sup>,
- 14) S(O)<sub>m</sub>R<sup>6</sup>, and
- 15) NO<sub>2</sub>;

25 m is independently 0, 1 or 2;

n is independently 0, 1, 2, 3, 4, 5 or 6;

s is 0 to 6;

t is 0, 1, or 2;

30 v is 0, 1 or 2;

w is 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.



3. The compound according to Claim 2 wherein:

R<sub>a</sub> is independently selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) Aryl, and
- 4) C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

said alkyl, aryl, and cycloalkyl is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>1</sup> is independently selected from:

- 1) H,
- 2) (CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 3) (CR<sup>a2</sup>)<sub>n</sub>C(O)R<sup>4</sup>,
- 4) C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 5) (CR<sup>a2</sup>)<sub>n</sub>OR<sup>4</sup>,
- 6) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 7) S(O)<sub>m</sub>R<sup>6</sup>,
- 8) S(O)<sub>m</sub>R<sup>6</sup>OR<sup>4</sup>,
- 9) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 10) C(O)N(R<sup>4</sup>)(CR<sup>a2</sup>)<sub>n</sub>OR<sup>4</sup>,
- 11) N(R<sup>4</sup>)S(O)<sub>m</sub>R<sup>6</sup>,
- 12) (CR<sup>a2</sup>)<sub>n</sub>C(O)OR<sup>4</sup>, and
- 13) R<sup>6</sup>C(O)OR;

R<sup>2</sup> is:

- 1) N(R<sup>4</sup>)<sub>2</sub>, or
- 2) OR<sup>4</sup>;

s is 0 to 3;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. The compound according to Claim 3 wherein:

R<sup>1</sup> is independently selected from:

- 1) H,
- 2) (CR<sup>a2</sup>)<sub>n</sub>R<sup>6</sup>,
- 3) (CR<sup>a2</sup>)<sub>n</sub>C(O)R<sup>4</sup>,
- 4) C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 5) (CR<sup>a2</sup>)<sub>n</sub>OR<sup>4</sup>,
- 6) (CR<sup>a2</sup>)<sub>n</sub>N(R<sup>4</sup>)<sub>2</sub>,
- 7) S(O)<sub>m</sub>R<sup>6</sup>, and
- 8) S(O)<sub>m</sub>R<sup>6</sup>OR<sup>4</sup>;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A compound selected from:

- 5-Chloro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 5-Bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 5-Iodo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 5-Methoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 6-Methoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 5-(Methylsulfonyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 7-Amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 3-(Morpholin-4-ylsulfonyl)-5-nitro-1*H*-indole-2-carboxamide;
- 5-Chloro-3-(piperazin-1-ylsulfonyl)-1*H*-indole-2-carboxamide;
- 3-[(4-Benzylpiperazin-1-yl)sulfonyl]-5-chloro-1*H*-indole-2-carboxamide;

3-[(4-Acetyl)piperazin-1-yl)sulfonyl]-5-chloro-1*H*-indole-2-carboxamide;

5-Chloro-3-(piperidin-1-ylsulfonyl)-1*H*-indole-2-carboxamide;

5 5-Chloro-3-(pyrrolidin-1-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Chloro-3-(thiomorpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Azetidin-1-ylsulfonyl)-5-chloro-1*H*-indole-2-carboxamide;

10

5-Chloro-3-[(oxidothiomorpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

15 *cis*-5-Chloro-3-(2,6-dimethylmorpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

*trans*-5-Chloro-3-(2,6-dimethylmorpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Chloro-3-[(3-hydroxyazetidin-1-yl)sulfonyl]-1*H*-indole-2-carboxamide;

20

(±)-5-Chloro-3-{[2-(phoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

(*S*)-5-Chloro-3-{[2-(phoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

25

(*R*)-5-Chloro-3-{[2-(phoxymethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

30 5-Bromo-3-({4-[2-(dimethylamino)ethyl]-5-oxo-1,4-diazepan-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-({5-oxo-1,4-diazepan-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

35 5-Bromo-3-[(3-oxopiperazin-1-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(3-hydroxyazetidin-1-yl)sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{{2-(aminocarbonyl)morpholin-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

5

3-(Azetidin-1-ylsulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-({4-[(4-methoxyphenyl)sulfonyl]piperazin-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

10

5-Bromo-3-({4-[(4-bromophenyl)sulfonyl]piperazin-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-{{4-(3-morpholin-4-ylpropyl)-3-oxopiperazin-1-yl}sulfonyl}-1*H*-indole-2-carboxamide;

15

5-Bromo-3-({4-[3-(dimethylamino)propyl]-3-oxopiperazin-1-yl}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-(2,5-dihydroxy-1*H*-pyrrol-1-ylsulfonyl)-1*H*-indole-2-carboxamide;

20

5-Bromo-3-(6-oxa-3-azabicyclo[3.1.0]hex-3-ylsulfonyl)-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{{2-(phenoxymethyl)morpholino-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

25

(*S*)-5-Bromo-3-{{2-(phenoxymethyl)morpholino-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

(*R*)-5-Bromo-3-{{2-(phenoxymethyl)morpholin-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

30

6-Hydroxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

35

5-(2-Furyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-(phenylethynyl)-1*H*-indole-2-carboxamide;

5 3-(Morpholin-4-ylsulfonyl)-5-(2-phenylethyl)-1*H*-indole-2-carboxamide;

5-Hex-1-ynyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Hexyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

10 Methyl 2-(aminocarbonyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-5-carboxylate;

3-(Morpholin-4-ylsulfonyl)-5-vinyl-1*H*-indole-2-carboxamide;

15 5-Hydroxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Ethoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-propoxy-1*H*-indole-2-carboxamide;

20 5-Isopropoxy-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Ethyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

25 2-(Aminocarbonyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indol-5-yl methanesulfonate;

3-(Morpholin-4-ylsulfonyl)-5-prop-1-ynyl-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-thien-2-yl-1*H*-indole-2-carboxamide;

30 3-(Azetidin-1-ylsulfonyl)-5-methoxy-1*H*-indole-2-carboxamide;

5-Formyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

35 5-Methyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-(Acetylamino)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-[(Methylsulfonyl)amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5

5- {[(4-Methoxyphenyl)amino]methyl}-3-morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

10

5- {[(2-Acetamide)amino]methyl}-3-morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholino-4-ylsulfonyl)-5-phenyl-1*H*-indole-2-carboxamide;

15

3-(Morpholino-4-ylsulfonyl)-5-pyrazin-2-yl-1*H*-indole-2-carboxamide;

3-(Morpholino-4-ylsulfonyl)-5-pyridin-2-yl-1*H*-indole-2-carboxamide;

3-(Morpholino-4-ylsulfonyl)-5-pyridin-4-yl-1*H*-indole-2-carboxamide;

20

5-(1-Benzofuran-2-yl)-3-(morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-(5-Methyl-2-furyl)-3-(morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

25

5-(3,5-Dimethylisoxazole-4-yl)-3-(morpholino-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-(1*H*-pyrrol-2-yl)-1*H*-indole-2-carboxamide;

30

3-(Morpholin-4-ylsulfonyl)-5-pyridin-3-yl-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-thien-3-yl-1*H*-indole-2-carboxamide;

35

5-(1-Benzothien-3-yl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Azetidin-1-yl)sulfonyl)-5-iodo-1*H*-indole-2-carboxamide;

3-[(3-Hydroxyazetidin-1-yl)sulfonyl]-5-iodo-1*H*-indole-2-carboxamide;

5

(±)-5-Iodo-3-{[2-(phenoxy)methyl]morpholino-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

(*S*)-5-Iodo-3-{[2-(phenoxy)methyl]morpholino-4-yl}sulfonyl}-1*H*-indole-2-

10

carboxamide;

(*R*)-5-Iodo-3-{[2-(phenoxy)methyl]morpholino-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

15

7-Amino-6-bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Amino-4,6-dibromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

6-Bromo-7-(dimethylamino)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

20

3-(Morpholin-4-ylsulfonyl)-7-[(pyridin-4-yl)methyl]amino]-1*H*-indole-2-carboxamide;

7-[[2-Chloropyridin-4-yl)methyl]amino}-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-

25

carboxamide;

7-Nitro-3-{[(2*S*)-2-(phenoxy)methyl]morpholin-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

30

7-Amino-3-{[(2*S*)-2-(phenoxy)methyl]morpholin-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

3-{[(2*S*)-2-(Phenoxy)methyl]morpholin-4-yl}sulfonyl}-7-[(pyridin-4-yl)methyl]amino]-1*H*-indole-2-carboxamide;

35

7-(Benzylamino)-3-{{[(2*S*)-2-(phenoxyethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

7-Chloro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5 6-Bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Bromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Cyano-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

10

(±)-7-(Methylsulfinyl)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

7-Aminomethyl-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

15 5-Amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

(*S*)-5-Fluoro-3-{{[2-(phenoxyethyl)morpholino-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

20 (*R*)-5-Fluoro-3-{{[2-(phenoxyethyl)morpholin-4-yl]sulfonyl}-1*H*-indole-2-carboxamide;

5-Acetylamino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

25 5-[(Methylsulfonyl)amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

3-(Morpholin-4-ylsulfonyl)-5-[(trifluoroacetyl)amino]-1*H*-indole-2-carboxamide;

30 5-[(2-Aminoethyl)amino]-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-(Dimethylamino)-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

4,5-Dibromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

35



5,6-Dibromo-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-4-nitro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-6-nitro-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5

5-Bromo-6-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-4-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide;

10

(*S*)-3-{{2-(Phenoxymethyl)morpholino-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({2-[(cyclohexylamino) carbonyl]morpholin-4-yl} sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1*H*-inden-1-ylamino)carbonyl] morpholin-4-yl} sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-phenylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{{(3-phenylpropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{{(3,3-diphenylpropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{{2-(3,4-dihydroisoquinolin-2(1*H*)-ylcarbonyl)morpholin-4-yl}sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-phenoxyethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1*H*-indole-2-carboxamide;

3-({2-[(3-Benzylpyrrolidin-1-yl)carbonyl]morpholin-4-yl} sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-{{(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

3-( { 2-[(Benzylamino)carbonyl]morpholin-4-yl} sulfonyl)-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[3-(trifluoromethyl)benzyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2,2-diphenylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]morpholin-4-yl} sulfonyl)-1H-indole-2-carboxamide;

7-{ [2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl] sulfonyl }-2-benzyl-7-aza-2-azoniaspiro[4.4]nonane;

5-Bromo-3-{[2-({[(5-methylpyrazin-2-yl)methyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

3-( { [(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}methyl)pyridine;

5-Bromo-3-[(2-{{(1-phenylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

1-(3-{[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}propyl)-1H-imidazole;

5-Bromo-3-{[2-({[(1R)-1-phenylethyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-phenylpropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-

2-carboxamide;

3-[(2-{[Benzyl(methyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

1-[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]-4-benzylpiperazine;

2-({[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}methyl)pyridine;

5-Bromo-3-{[2-({[2-(tert-butylthio)ethyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

3-({2-[(Benzhydrylamino)carbonyl]morpholin-4-yl}sulfonyl)-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[2-({[(2S)-2-phenylcyclopropyl]amino}carbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(3-phenylpyrrolidin-1-yl)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(4,4-diphenylpiperidin-1-yl)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[(2-({[(2,3-dihydro-1H-inden-2-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1H-inden-1-ylamino)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(2,3-dihydro-1H-inden-1-ylamino)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(3-pyridin-4-ylpyrrolidin-1-yl)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(4-hydroxy-4-phenylpiperidin-1-yl)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

3-{[2-(Anilinocarbonyl)morpholin-4-yl}sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-oxo-2-phenylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-({2-[(neopentylamino)carbonyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(1,2-diphenylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(4-chlorophenyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(4-phenoxyphenyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(4-tert-butylphenyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{{2-({[3-(2-oxopyrrolidin-1-yl)propyl]amino}carbonyl)morpholin-4-yl}sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(3-isopropoxypropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-

indole-2-carboxamide;

5-Bromo-3-[(2-{{(3-ethoxypropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-cyclohex-1-en-1-ylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2,2,3,3,4,4,4-heptafluorobutyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(3-isobutoxypropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(3-butoxypropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-thien-2-ylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

2-({[(4-{{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}methyl)-1H-benzimidazole;

3-{{[2-(Azepan-1-ylcarbonyl)morpholin-4-yl]sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-({2-[[2-{{(2,6-dichlorobenzyl)thio}ethyl}amino}carbonyl]morpholin-4-yl)sulfonyl)-1H-indole-2-carboxamide;

3-{{[2-{{[4-(Aminosulfonyl)benzyl]amino}carbonyl}morpholin-4-yl]sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{{[2-(thiomorpholin-4-ylcarbonyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-methoxyethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(2-methoxy-1-methylethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(1-ethylpropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[[2-({[6-(dimethylamino)hexyl]amino}carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(tetrahydrofuran-2-ylmethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(1-phenylcyclopropyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[[2-({[phenyl(pyridin-4-yl)methyl]amino}carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(dicyclopropylmethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{{(1,4-dioxan-2-ylmethyl)amino}carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[[2-({methyl[2-(4-methylphenoxy)ethyl]amino}carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[[2-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}carbonyl)morpholin-4-yl]sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{[2-(2-phenylethyl)pyrrolidin-1-yl]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{[(2-cyclohexylethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

4-({[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}methyl)-1-methyl-1H-imidazole;

5-Bromo-3-[(2-{[(1,1-dioxotetrahydrothien-3-yl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{[(1-naphthylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(2-{[(imidazo[2,1-b][1,3]thiazol-6-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide;

3-[(2-{[2-(1,3-Benzothiazol-2-yl)pyrrolidin-1-yl]carbonyl}morpholin-4-yl)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

5-Chloro-3-({2-[(2-ethoxyphenoxy)methyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

5-Chloro-3-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylsulfonyl]-1H-indole-2-carboxamide;

7-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-3-benzyl-9-thia-7-aza-3-azoniabicyclo[3.3.1]nonane;

5-Chloro-3-([2-(1H-indol-4-yl)morpholin-4-yl]sulfonyl)-1H-indole-2-carboxamide;

5-Chloro-3-(2,3-dihydro-1,4-benzoxazepin-4(5H)-ylsulfonyl)-1H-indole-2-carboxamide;

3-[(Benzofuran-yl-1-oxa-8-azaspiro[4.5]dec-8-yl)sulfonyl]-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[4-fluoro-4-(3-phenylpropyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

3-[(3-Benzyl-1-oxa-8-azaspiro[4.5]dec-8-yl)sulfonyl]-5-chloro-1H-indole-2-carboxamide;

3-({4-[(Benzyloxy)methyl]-4-phenylpiperidin-1-yl}sulfonyl)-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[4-hydroxy-4-(3-phenylpropyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

7-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-2-(4-chlorophenyl)-7-aza-2-azoniaspiro[4.4]nonane;

3-(1-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-3-yl)-4-methyl-4H-1,2,4-triazole;

5-Chloro-3-{[3-(2-phenylethyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[3-(2-phenylethyl)pyrrolidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[4-(cyclopropyl){3-(trifluoromethyl)phenyl}sulfonyl]amino}piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-({2-[(4-chlorophenoxy)methyl]morpholin-4-yl}sulfonyl)-1H-indole-2-carboxamide;

Tert-butyl (1-{[2-(aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-3-yl)acetate;



3-[(3-Benzylpiperidin-1-yl)sulfonyl]-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[3-(2-methylphenyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

2-(1-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-4-yl)-N,N-dimethylethanamine;

1-(1-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}piperidin-4-yl)-3-(ethoxycarbonyl)piperidine;

5-Bromo-3-{[3-(4-tert-butoxybenzyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[4-(3-phenylpropyl)piperidin-1-yl]sulfonyl}-1H-indole-2-carboxamide;


5-Bromo-N-methoxy-N-methyl-3-{[2-(phenoxyethyl)morpholin-4-yl]sulfonyl}-1H-indole-2-carboxamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.


6. The compound according to Claim 5 that is selected from

5


3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide




(S)-5-Iodo-3-{[2-(phenoxyethyl)morpholino-4-yl]sulfonyl}-1H-indole-2-carboxamide




5-Bromo-6-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide




5-bromo-3-({2-[(2,3-dihydro-1*H*-inden-2-ylamino)carbonyl]morpholin-4-yl}sulfonyl)-1*H*-indole-2-carboxamide



5-bromo-3-{{2-([2-(tert-butylthio)ethyl]amino)carbonyl]morpholin-4-yl}sulfonyl}-1*H*-indole-2-carboxamide



5-bromo-3-[(2-[(1-naphthylmethyl)amino]carbonyl)morpholin-4-yl)sulfonyl]-1H-indole-2-carboxamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

5

7. A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

8. A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

10

9. The method of Claim 7 wherein the protein kinase is an RTK.

15

10. The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.

20

11. A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

12. A method of Claim 11, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

25

- 1) cancer,
- 2) diabetes,
- 3) an autoimmune disorder,
- 4) a hyperproliferation disorder,

- 5) aging,
- 6) acromegaly, and
- 7) Crohn's disease.

5                   13. A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

10                   14. A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

15                   15. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 20                   5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 25                   10) an angiogenesis inhibitor.

16. The method of Claim 15, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

30                   17. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

35                   18. The method of Claim 15 wherein radiation therapy is also administered.

19. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

5 20. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

10 21. The method of Claim 20 wherein the GPIIb/IIIa antagonist is tirofiban.

22. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.